Eastgate Biotech (ETBI) 10-K 1 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document and Entity Information:
Entity Registrant Name	EASTGATE BIOTECH CORP
Entity Central Index Key	1099574
Trading Symbol	etbi
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		125,414,792
Entity Public Float			$6,270,739
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current
Cash	$286,481	$458
Sales tax recoverable	53,208
Total current assets	339,689	458
Other assets
Property & Equipment, net	143,246	71,297
Total other assets	143,246	71,297
Total assets	482,935	71,755
Current liabilities
Accounts payable and accrued liabilities	299,099	421,439
Accrued liabilities related party	388,675	960,000
Deferred rent	4,200
Capital lease obligation		24,380
Accrued interest - related parties	182,845	95,004
Notes payable - related parties	1,006,391	898,109
Total current liabilities	1,881,210	2,398,932
Long term liabilities
Capital lease obligation long term
Total long term liabilities
Total Liabilities	1,881,210	2,398,932
Commitments and Contingencies
Stockholders' equity (deficit)
Authorized: Preferred stock:50,000,000 shares authorized at $0.00001 par value no shares issued at December 31, 2014 and December 31, 2013
Common stock: 450,000,000 shares authorized at $0.00001 par value 89,635,234 and 31,625,000 shares issued and outstanding at December 31, 2014 and December 31, 2013 respectively	896	316
Additional paid-in capital	5,957,771	134,884
Subscription payable		2,000
Accumulated other comprehensive income	15,268	147
Accumulated deficit	-7,372,210	-2,464,524
Total stockholders' Equity (Deficit)	-1,398,275	-2,327,177
Total liabilities and stockholders' equity (deficit)	$482,935	$71,755

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	450,000,000	450,000,000
Common stock, issued	89,635,234	31,625,000
Common stock, outstanding	89,635,234	31,625,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
REVENUES
Cost of goods sold
Gross (loss) profit
OPERATING EXPENSES
Professional fees	177,679	52,524
Research & development	840,240	132,092
General and administrative	3,724,648	1,445,912
Marketing and selling	76,240	25,554
Total Operating Expenses	4,818,807	1,656,082
LOSS FROM OPERATIONS	-4,818,807	-1,656,082
Other items
Interest expense	-88,879	-64,234
Total other items	-88,879	-64,234
LOSS BEFORE INCOME TAXES	-4,907,686	-1,720,316
PROVISION FOR INCOME TAXES
NET LOSS	-4,907,686	-1,720,316
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)	($0.10)	($0.05)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC & DILUTED (in shares)	49,526,133	31,625,000
A summary of the components of other comprehensive loss for the periods ended is as follows:
Net Loss	-4,907,686	-1,720,316
Other Comprehensive Loss - foreign currency translation	15,121	147
Comprehensive Loss	($4,892,565)	($1,720,169)

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (Deficit) (USD $)	Common Stock	Additional Paid-In Capital	Subscription Payable	Accumulated other comprehensive income	Deficit Accumulated During the Development Stage	Total
Balance at Dec. 31, 2012	$316	$134,884			($744,208)	($609,008)
Balance (in shares) at Dec. 31, 2012	31,625,000
Subscription payable			2,000			2,000
Translation adjustment				147		147
Net loss for the period					-1,720,316	-1,720,316
Balance at Dec. 31, 2013	316	134,884	2,000	147	-2,464,524	-2,327,177
Balance (in shares) at Dec. 31, 2013	31,625,000					31,625,000
Shares issued in conversion of accrued compensation	252	834,377				834,629
Shares issued in conversion of accrued compensation (in shares)	25,167,355
Shares issued for services	103	1,477,776				1,477,879
Shares issued for services (in shares)	10,322,233
Shares issued in conversion of accrued accounts payable	8	114,351				114,359
Shares issued in conversion of accrued accounts payable (in shares)	819,246
Private placement (shares & warrants issued for cash)	133	1,548,367	-2,000			1,546,500
Private placement (shares & warrants issued for cash) (in shares)	13,309,000
Shares and warrants (units) issued for accrued compensation	74	1,848,026				1,848,100
Shares and warrants (units) issued for accrued compensation (in shares)	7,392,400
Translation adjustment				15,121		15,121
Stock issued for placement services	10	-10
Stock issued for placement services (in shares)	1,000,000
Net loss for the period					-4,907,686	-4,907,686
Balance at Dec. 31, 2014	$896	$5,957,771		$15,268	($7,372,210)	($1,398,275)
Balance (in shares) at Dec. 31, 2014	89,635,234					89,635,234

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	($4,907,686)	($1,720,316)
Adjustments to reconcile net loss to net cash used by operating activities:
Expenses paid on the Company's behalf by a related party	4,937	81,584
Common stock issued for services	1,477,879
Depreciation	27,875	14,519
Changes in operating assets and liabilities:
Accrued interest	87,840	59,849
Prepaid asset		4,500
Accounts payable	47,363	192,189
Accrued liabilities related party	2,069,912	960,000
Sales tax recoverable	-56,054
Long term deposit
Deferred rent	4,425
Cash flows used from operating activities	-1,243,510	-407,675
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	-99,823	-22,273
Cash flows used from investing activities	-99,823	-22,273
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of capital lease obligation	-24,380	-39,163
Proceeds from notes payable related party	190,880	367,422
Payments on notes payable related party	-87,536	2,000
Common stock issued for cash	1,546,500
Cash flows provided by financing activities	1,625,464	330,259
NET INCREASE (DECREASE) IN CASH	282,131	-99,689
Effect of foreign currency translation adjustments	3,892	147
Cash, beginning of the period	458	100,000
Cash, end of the period	286,481	458
Supplemental disclosures of cash flow information:
Cash paid for income taxes
Cash paid for interest	1,175	4,386
Non Cash Financing activities:
Property & equipment purchased under capital lease obligation		63,543
Common stock issued to convert liabilities	2,797,088
Common stock issued - subscription payable	2,000
Common stock issued for placement fees	$10

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Eastgate Biotech Corp. (The Company) was organized on September 8, 1999, under the laws of the State of Nevada. The Company is a development stage company which has limited history of operations is engaged in the research and development of drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. During the year ended December 31, 2012 the Company formed Eastgate Pharmaceuticals, Inc. as a wholly-owned subsidiary of the Company.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
	Development Stage Company
	The accompanying consolidated financial statements have been prepared in accordance with the provision of FASB ASC Topic 915, Development Stage Entities."
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
	Property and Equipment
	Property and equipment are recorded at cost and are depreciated when placed into service using the straight-line method based on their estimated useful lives of five year. Equipment under capital leases are stated at the lower of fair market value or net present value of the minimum lease payments at the inception of the leases.
	Research and Development Costs
	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.
	Impairment of Long-Lived Assets
	The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
	Income Taxes
	The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 39% to net the loss before provision for income taxes for the following reasons:
		December 31,			December 31,
		2014			2013
	Income tax expense at statutory rate	$	(1,913,997	)	$	(670,860	)
	Contributed services
	Stock issued for services		576,373			-
	Depreciation and amortization		10,871			5,662
	Change in valuation allowance		1,326,753			665,198
	Income tax expense per books	$	-0-		$	-0-
	Net deferred tax assets consist of the following components as of:
		December 31,			December 31,
		2014			2013
	NOL carryover	$	2,875,099		$	961,102
	Valuation allowance		(2,875,099	)		(961,102	)
	Net deferred tax asset	$	-0-		$	-0-
	Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $5,724,776 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.
	Earnings (Loss) per Share
	The Company has adopted ASC 260, "Earnings Per Share," ("EPS") which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures, and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.
	The Company has 17,272,300 and 0 potentially dilutive securities, comprised of warrants issued as of Decemeber 31, 2014 and 2013, respectively.
	Comprehensive Loss
	Other comprehensive loss, which includes only foreign currency translation adjustments, is shown in the Statement of Operations.
	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary's financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders' equity.
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information.
	The Company has evaluated all other recent accounting pronouncements and their adoption has not had nor is not expected to have a material impact on the Company's financial position or statements.
	Accounting Basis
	The basis is accounting principles generally accepted in the United States of America. The Company has adopted a December 31 fiscal year end.

GOING_CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2014
Going Concern [Abstract]
GOING CONCERN	NOTE 2 - GOING CONCERN
	The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern.  However, the Company has accumulated deficit of $7,372,210 as of December 31, 2014.  The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time, raising substantial doubt about its ability to continue as a going concern.
	Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED-PARTY TRANSACTIONS	NOTE 3 - RELATED-PARTY TRANSACTIONS
	Notes payable – related parties
	The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet. The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum, are unsecured and are due and payable upon demand.
	During the year ended December 31, 2014 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have paid for expenses on behalf of the Company of  $4,938,  advanced cash to the Company of $190,880 and the Company made payments on the notes payable of $87,536. During the year ended December 31, 2013 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have paid for expenses on behalf of the Company of $81,584, advanced cash to the Company of $367,422.  As of December 31, 2014 and 2013, the Company owed $182,845 and $95,004 of accrued interest to related parties, respectively, resulting from interest expense of $88,879 and $59,848, respectively.
	Officer Compensation
	In the year ended December 31, 2014 the Company recorded executive compensation expense to the CEO of $359,749 which was recorded in accrued liabilities-related party.  In addition, services provided by other officers and management of the Company amounting to an expense of $1,382,207 was recorded in accrued liabilities related party. Some of the balances accumulated in accrued liabilities related party totaling $2,313,281 were converted to common stock at the then prevailing market price ranging from $0.032 to $0.25 per share leaving a balance of $388,675 at December 31, 2014.   In the year ended December 31, 2013 the Company recorded compensation expense to the CEO of $216,000 which is recorded in accrued liabilities related party.  In addition, services provided by other officers and management of the Company amounting to an expense of $744,000 was recorded in accrued liabilities related party.
	Lease payable – related parties
	The Company has entered into a lease agreement on July 1, 2012 for the use of operating space owned by our President, which expires on June 30, 2017.  The lease agreement is for the use of the office space at a monthly rate of approximately $3,171 per month.  (See Note 6.)

PROPERTY_EQUIPMENT_AND_CAPITAL

PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION	NOTE 4 – PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION
	On January 4, 2013 the Company entered into a capital lease agreement to purchase equipment. The lease had a term of 19 months starting January 4, 2013 with the final payment due on August 1, 2014. The lease specified a monthly rate of $3,600. The lease required minimum lease payments of $68,400 over the term of the lease. The lease was initially recorded at $63,543, which is the present value of the minimum lease payments (less no executor cost) using the Company's incremental borrowing rate of 10%. During the twelve months ended December 31, 2013 the Company paid principal of $39,163 against the capital lease obligation and corresponding interest of $4,037, leaving an amount owing at the end of the period of $24,380. This balance was repaid in full during fiscal 2014 that included $820 in interest.
	During the twelve months ending December 31, 2014, the Company purchased additional equipment for cash of $99,823. The estimated useful life of equipment purchased during the year ended December 31, 2014 is 5 years. During the twelve months ending December 31, 2013, the Company purchased additional equipment for cash of $22,273. The estimated useful life of all equipment purchased during the year ended December 31, 2013 is also 5 years. Depreciation expense of $27,874 and $14,519 was recorded during the year ended December 31, 2014 and December 31, 2013, respectively, which leaves a net balance in Property & Equipment of $143,246 and $71,297 at December 31, 2014 and December 31, 2013, respectively.
	The costs and accumulated depreciation of property and equipment are summarized as follows:
		December 31,			December 31,
		2014			2013
	Lab Equipment	$	185,639		$	85,816
	Less: Accumulated Depreciation		(42,393	)		(14,519	)
	Property and Equipment, Net	$	143,246		$	71,297

SALES_TAX_RECOVERABLE

SALES TAX RECOVERABLE	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
SALES TAX RECOVERABLE	NOTE 5 –SALES TAX RECOVERABLE
	Sales tax receivable
	The Company recovers sales tax paid, for which returns are filed on annual basis. At December 31, 2014, $53,208 was claimed as recoverable compared to the December 31, 2013 balance of $0.  Sales tax recoverable is a result of sales tax paid on eligible expenses.

COMMITMENTS_AND_CONTINGENT_LIA

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6 – COMMITMENTS AND CONTINGENT LIABILITIES
	Operating Lease
	The Company has assumed a lease agreement from a company controlled by the CEO on October 31, 2012 for the use of operating space owned by a third party, which expires on May 16, 2017.
	The Company has entered into a lease agreement on July 1, 2012 for the use of operating space owned by President, which expires on June 30, 2017.
	Aggregate minimum annual lease commitments of the Company under non-cancelable operating leases as of December 31, 2014 are as follows:
	Year	Amount
	2015	$	94,944
	2016		94,944
	2017		42,570
	Thereafter		0
	Total Minimum Lease Payments	$	232,458
	Lease expense amounted to $123,319 and $69,984 for the years ended December 31, 2014 and 2013, respectively.
	The preceding data reflects existing leases and does not include replacements upon their expiration.  In the normal course of business, operating leases are generally renewed or replaced by other leases.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 7 – STOCKHOLDERS' EQUITY
	On September 15, 2014, the board of directors and the shareholders holding a majority of our common stock approved amending our Restated Articles of Incorporation to 1) change our name to "Eastgate Biotech Corp." from "Eastgate Acquisitions Corporation" and 2) increase our total number of shares of authorized capital stock to 500,000,000 shares consisting of (i) 450,000,000 shares of common stock and (ii) 50,000,000 shares of preferred stock.  Also on September 15, 2014 shareholders holding a majority of our common stock approved the Company's 2014 Equity Incentive Plan, which was previously approved by the board of directors on May 20, 2014.  The name change and increase in authorized shares will become effective when we amended the Restated Articles of Incorporation by filing a Certificate of Amendment with the Secretary of State of Nevada on November 20, 2014.
	During the quarter ended March 31, 2014 the Company sold 4,190,000 Units at $0.25 and 450,000 Units at $0.22 consisting of one share of common stock and a warrant to purchase 0.75 of a share for cash pursuant to a private placement agreement.  As a result of this transaction, the Company issued 4,640,000 shares of common stock and 3,480,000 warrants to purchase our common stock for five years at $0.25 per share.  The Company issued 1,000,000 shares and paid $110,000 in cash in finder's fee in connection with this transaction.
	Also, during the quarter ended March 31, 2014 the Company issued 4,660,000 Units consisting of one share of common stock and a warrant to purchase 0.75 of a share in satisfaction of accrued liabilities at the price of $0.25 per share.  As a result of this transaction, the Company issued 4,660,000 shares of common stock and 3,495,000 warrants to purchase our common stock for five years at $0.25 per share.  The Units were issued on the same terms as the Units issued in connection with the private placement transaction.
	Additionally, during the quarter ended March 31, 2014 the Company issued a total of 1,073,000 shares of common stock to employees and consultants for services rendered at the price of $0.25 per share.
	During the quarter ended March 31, 2014 the Company issued 321,628 shares of common stock to vendors in satisfaction of accounts payable and accrued liabilities at the price of $0.25 per share.
	During the quarter ended June 30, 2014 the Company has sold 244,000 Units consisting of one share of common stock and a warrant to purchase 0.75 of a share for cash pursuant to a private placement agreement at the price of $0.25 per share.  As a result of this transaction, the Company issued 244,000 shares of common stock and 183,000 warrants to purchase our common stock for five years at $0.25 per share.
	During the quarter ended June 30, 2014 the Company has issued 2,452,400 Units consisting of one share of common stock and a warrant to purchase 0.75 of a share in satisfaction of accrued liabilities at the price of $0.25 per share.  As a result of this transaction, the Company issued 2,452,400 shares of common stock and 1,839,300 warrants to purchase our common stock for five years at $0.25 per share.  The 2,452,400 Units were issued on the same terms as the Units issued in connection with the private placement transaction.
	During the quarter ended June 30, 2014 the Company issued a total of 3,572,000 shares of common stock to consultants for services rendered at the price of $0.25 per share.
	During the quarter ended June 30, 2014 the Company issued 280,000 shares of common stock to two officers as part of their compensation at the price of $0.25 per share.
	During the quarter ended September 30, 2014 the Company issued a total of 977,233 shares of common stock to consultants for services rendered at the price ranging from $0.06 to $0.50 per share.
	During the quarter ended September 30, 2014 the Company issued a total of 841,191 shares of common stock to consultants for services rendered at the price of $0.06 per share.
	During the quarter ended September 30, 2014 the Company issued a total of 118,142 shares of common stock to consultants for services rendered at the price of $0.48 per share.
	During the quarter ended September 30, 2014 the Company issued a total of 17,900 shares of common stock to consultants for services rendered at the price of $0.50 per share.
	During the quarter ended September 30, 2014 the Company issued 1,770,346 shares of common stock to two officers and an employee as part of their compensation at the price of $0.055 per share.
	During the quarter ended December 31, 2014 the Company issued a total of 1,700,000 shares of common stock to consultants for services rendered at the price of $0.065 per share.
	During the quarter ended December 31, 2014 the Company sold 300,000 Units at a purchase price of $0.05 per Unit in a private placement of its securities to accredited investors for total proceeds of $15,000.  Each Unit consisted  of one share of common stock and a five year warrant to purchase 0.5 of a share at an exercise price of $0.05 per share.  As a result of this transaction, the Company issued 300,000 shares of common stock and 150,000 warrants.
	During the quarter ended December 31, 2014 the Company issued a total of 23,894,627 shares of common stock in satisfaction of accrued liabilities at the price of $0.32 per share.
	During the quarter ended December 31, 2014 the Company issued 3, 000,000 shares of common stock to a consultant for services rendered at the price of $0.03 per share.
	During the quarter ended December 31, 2014 the Company sold 8,125,000 Units at a purchase price of $0.04 per Unit in a private placement of its securities to accredited investors for total proceeds of $325,000.  Each Unit consisted of one share of common stock and a five year warrant to purchase one share of common stock at an exercise price of $0.04 per share.  As a result of this transaction, the Company issued 8,125,000 shares of common stock and 8,125,000 warrants to purchase our common stock.
	As of December 31, 2014, the Company had 17,272,300 warrants to purchase common stock.  The warrants have a weighted average price of $0.15 per share and have a weighted average remaining life of 4.62 years.
	The following table summarizes warrants that are issued, outstanding and exercisable
				Warrants Issued & Outstanding
	Exercise		Expiration	December 31,		December 31,
	Price		Date	2014		2013
	$	0.25	14-Mar-19		3,495,000		-
	$	0.25	21-Mar-19		3,480,000		-
	$	0.25	6-Jun-19		2,022,300		-
	$	0.05	16-Oct-19		150,000		-
	$	0.04	29-Dec-19		8,125,000		-
					17,272,300		-

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS
	In accordance with ASC 855 Company management reviewed all material events through the date of this report.
	On January 5, 2015 the Company issued 8,146,225 Units of its securities in satisfaction of accrued liabilities at the price of $0.04 per share.  Each Unit consisted of one share of common stock and a five year warrant to purchase one share of common stock at an exercise price of $0.04 per share.     As a result of this transaction, the Company issued 8,146,225 shares of common stock and 8,146,225 warrants to purchase our common stock.
	In January 2015 the Company issued a total of 3,700,000 shares of common stock to consultants for services rendered at the price of $0.035 per share.
	On February 12, 2015 the Company issued a total of 15,250,000 shares of common stock to employees and consultants for services rendered at the price of $0.0286 per share.
	On February 12, 2015 the Company issued a total of 10,375,000 options to purchase shares of common stock to employees and consultants as compensation at the price of $0.0286 per share.  The total fair value of the options at the date of the grant was $201,619.  The options vested immediately and a charge of $201,619 was recorded as of grant date.  The fair value was estimated using the Black-Scholes option pricing model, taking into account the grant date exercise price of $0.0286, an expected life of the option of 2.5 years, an expected volatility of 211.1%, expected dividends on the stock of 0 and the risk-free interest rate for the term of the option of  1.02%.
	In March 2015 the Company issued a total of 8,683,333 shares of common stock to consultants for services rendered at the price of $0.033 per share.

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
Development Stage Company	Development Stage Company
	The accompanying consolidated financial statements have been prepared in accordance with the provision of FASB ASC Topic 915, Development Stage Entities."
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
Property and Equipment	Property and Equipment
	Property and equipment are recorded at cost and are depreciated when placed into service using the straight-line method based on their estimated useful lives of five year. Equipment under capital leases are stated at the lower of fair market value or net present value of the minimum lease payments at the inception of the leases.
Research and Development Costs	Research and Development Costs
	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
Income Taxes	Income Taxes
	The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 39% to net the loss before provision for income taxes for the following reasons:
		December 31,			December 31,
		2014			2013
	Income tax expense at statutory rate	$	(1,913,997	)	$	(670,860	)
	Contributed services
	Stock issued for services		576,373			-
	Depreciation and amortization		10,871			5,662
	Change in valuation allowance		1,326,753			665,198
	Income tax expense per books	$	-0-		$	-0-
	Net deferred tax assets consist of the following components as of:
		December 31,			December 31,
		2014			2013
	NOL carryover	$	2,875,099		$	961,102
	Valuation allowance		(2,875,099	)		(961,102	)
	Net deferred tax asset	$	-0-		$	-0-
	Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $5,724,776 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.
Earnings (Loss) per Share	Earnings (Loss) per Share
	The Company has adopted ASC 260, "Earnings Per Share," ("EPS") which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures, and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.
	The Company has 17,272,300 and 0 potentially dilutive securities, comprised of warrants issued as of Decemeber 31, 2014 and  2013, respectively.
Comprehensive Loss	Comprehensive Loss
	Other comprehensive loss, which includes only foreign currency translation adjustments, is shown in the Statement of Operations.
Foreign Currency Translation	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period.  Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period.  Translation adjustments that arise from translating the foreign subsidiary's financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders' equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information.
	The Company has evaluated all other recent accounting pronouncements and their adoption has not had nor is not expected to have a material impact on the Company's financial position or statements.
Accounting Basis	Accounting Basis
	The basis is accounting principles generally accepted in the United States of America.  The Company has adopted a December 31 fiscal year end.

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of provision for income taxes		December 31,			December 31,
		2014			2013
	Income tax expense at statutory rate	$	(1,913,997	)	$	(670,860	)
	Contributed services
	Stock issued for services		576,373			-
	Depreciation and amortization		10,871			5,662
	Change in valuation allowance		1,326,753			665,198
	Income tax expense per books	$	-0-		$	-0-
Schedule of Components of net deferred tax assets		December 31,			December 31,
		2014			2013
	NOL carryover	$	2,875,099		$	961,102
	Valuation allowance		(2,875,099	)		(961,102	)
	Net deferred tax asset	$	-0-		$	-0-

PROPERTY_EQUIPMENT_AND_CAPITAL1

PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of property and equipment		December 31,			December 31,
		2014			2013
	Lab Equipment	$	185,639		$	85,816
	Less: Accumulated Depreciation		(42,393	)		(14,519	)
	Property and Equipment, Net	$	143,246		$	71,297

COMMITMENTS_AND_CONTINGENT_LIA1

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of minimum annual lease commitments under non-cancelable operating leases	Year	Amount
	2015	$	94,944
	2016		94,944
	2017		42,570
	Thereafter		0
	Total Minimum Lease Payments	$	232,458

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Summarizes warrants that are issued, outstanding and exercisable				Warrants Issued & Outstanding
	Exercise		Expiration	December 31,		December 31,
	Price		Date	2014		2013
	$	0.25	14-Mar-19		3,495,000		-
	$	0.25	21-Mar-19		3,480,000		-
	$	0.25	6-Jun-19		2,022,300		-
	$	0.05	16-Oct-19		150,000		-
	$	0.04	29-Dec-19		8,125,000		-
					17,272,300		-

ORGANIZATION_AND_SUMMARY_OF_SI3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Income tax expense at statutory rate	($1,913,997)	($670,860)
Contributed services
Stock issued for services	576,373
Depreciation and amortization	10,871	5,662
Change in valuation allowance	1,326,753	665,198
Income tax expense per books

ORGANIZATION_AND_SUMMARY_OF_SI4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
NOL carryover	$2,875,099	$961,102
Valuation allowance	-2,875,099	-961,102
Net deferred tax asset

ORGANIZATION_AND_SUMMARY_OF_SI5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Depreciation method	Straight-line method
Estimated useful life of equipment	5 years	5 years
Statutory federal income tax rate	39.00%
Net operating loss carry forwards for federal tax purposes	$5,724,776
Potentially dilutive securities, comprised of warrants issued	17,272,300	0

GOING_CONCERN_Detail_Textuals

GOING CONCERN (Detail Textuals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Going Concern [Abstract]
Accumulated deficit	($7,372,210)	($2,464,524)

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Expenses paid on the Company's behalf by a related party	$4,937	$81,584
Advanced cash received	190,880	367,422
Repayment of related party loan	87,536	-2,000
Accrued interest to related parties	182,845	95,004
Interest expense	88,879	64,234
Amount of accrued liabilities related party converted to common stock	2,313,281
Balance of accrued liabilities related party	388,675	960,000
Notes payable - related parties
Related Party Transaction [Line Items]
Interest rate, minimum	5.00%
Interest rate, maximum	10.00%
Expenses paid on the Company's behalf by a related party	4,938	81,584
Advanced cash received	190,880	367,422
Repayment of related party loan	87,536
Accrued interest to related parties	182,845	95,004
Interest expense	88,879	59,848
Minimum
Related Party Transaction [Line Items]
Market price (in dollars per share)	$0.03
Maximum
Related Party Transaction [Line Items]
Market price (in dollars per share)	$0.25
CEO
Related Party Transaction [Line Items]
Executive compensation expense	359,749	216,000
Accrued liabilities related party	1,382,207	744,000
President
Related Party Transaction [Line Items]
Office space monthly rate per month	$3,171

PROPERTY_EQUIPMENT_AND_CAPITAL2

PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Lab Equipment	$185,639	$85,816
Less: Accumulated Depreciation	-42,393	-14,519
Property and Equipment, Net	$143,246	$71,297

PROPERTY_EQUIPMENT_AND_CAPITAL3

PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION (Detail textuals) (USD $)	0 Months Ended	12 Months Ended
	Jan. 04, 2013	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Capital lease term of agreement	19 months
Capital leases monthly rate	$3,600
Capital leases minimum lease payments	68,400
Present value of minimum lease payments	63,543
Incremental borrowing rate	10.00%
Payment of principal for capital lease obligation			39,163
Capital lease interest expense		820	4,037
Capital lease obligations			24,380
Purchase of additional equipment for cash		99,823	22,273
Estimated useful life of equipment		5 years	5 years
Depreciation expense		27,875	14,519
Property & Equipment, net		$143,246	$71,297

SALES_TAX_RECOVERABLE_Detail_T

SALES TAX RECOVERABLE (Detail Textuals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Sales tax recoverable	$53,208

COMMITMENTS_AND_CONTINGENT_LIA2

COMMITMENTS AND CONTINGENT LIABILITIES (Details) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$94,944
2016	94,944
2017	42,570
Thereafter
Total Minimum Lease Payments	$232,458

COMMITMENTS_AND_CONTINGENT_LIA3

COMMITMENTS AND CONTINGENT LIABILITIES (Detail textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Lease expense	$123,319	$69,984

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Exercise Price	$0.15
Warrants Issued & Outstanding	17,272,300
14-Mar-19
Class of Warrant or Right [Line Items]
Exercise Price	$0.25
Warrants Issued & Outstanding	3,495,000
21-Mar-19
Class of Warrant or Right [Line Items]
Exercise Price	$0.25
Warrants Issued & Outstanding	3,480,000
6-Jun-19
Class of Warrant or Right [Line Items]
Exercise Price	$0.25
Warrants Issued & Outstanding	2,022,300
16-Oct-19
Class of Warrant or Right [Line Items]
Exercise Price	$0.05
Warrants Issued & Outstanding	150,000
29-Dec-19
Class of Warrant or Right [Line Items]
Exercise Price	$0.04
Warrants Issued & Outstanding	8,125,000

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDERS' EQUITY (Detail Textuals) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Jun. 30, 2014	Sep. 30, 2014	Sep. 15, 2014	Dec. 31, 2013
Stockholders Equity Note [Line Items]
Total number of shares of authorized capital stock						500,000,000
Common stock, shares authorized	450,000,000		450,000,000			450,000,000	450,000,000
Preferred stock, shares authorized	50,000,000		50,000,000			50,000,000	50,000,000
Number of warrants to purchase common stock	17,272,300		17,272,300
Exercise price	$0.15		$0.15
Weighted average life	4 years 7 months 13 days
Employee and Consultant
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)		1,073,000
Price per share		$0.25
Vendor
Stockholders Equity Note [Line Items]
Shares issued in satisfaction of accounts payable and accrued liabilities		321,628	23,894,627
Price per share	$0.32	$0.25	$0.32
Consultant
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)				3,572,000
Price per share				$0.25
Consultant | Stock issued for services one
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)			1,700,000		977,233
Price per share	$0.07		$0.07
Consultant | Stock issued for services one | Minimum
Stockholders Equity Note [Line Items]
Price per share					0.06
Consultant | Stock issued for services one | Maximum
Stockholders Equity Note [Line Items]
Price per share					0.5
Consultant | Stock issued for services two
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)			3,000,000		841,191
Price per share	$0.03		$0.03		0.06
Consultant | Stock issued for services three
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)					118,142
Price per share					0.48
Consultant | Stock issued for services four
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)					17,900
Price per share					0.5
Officer
Stockholders Equity Note [Line Items]
Price per share				$0.25	0.055
Shares issued as compensation				280,000	1,770,346
Entity Number of Employees				2	2
Common stock and warrant unit
Stockholders Equity Note [Line Items]
Number of common stock represents by unit		1
Number of warrants represents by unit		0.75
Common stock shares issued		4,640,000
Number of warrants to purchase common stock		3,480,000
Exercise price		$0.25
Weighted average life		5 years
Shares issued in connection with finders fee		1,000,000
Payment in cash		$110,000
Common stock and warrant unit | Unit Issued one
Stockholders Equity Note [Line Items]
Number of units issued		4,190,000
Units issue price		0.25
Common stock and warrant unit | Unit Issued two
Stockholders Equity Note [Line Items]
Number of units issued		450,000
Units issue price		0.22
Common stock and warrant unit | Units issued three
Stockholders Equity Note [Line Items]
Number of units issued			300,000
Units issue price			0.05
Proceeds from sale of units			15,000
Number of common stock represents by unit			1
Number of warrants represents by unit			0.5
Common stock shares issued			300,000
Number of warrants to purchase common stock	150,000		150,000
Exercise price	$0.05		$0.05
Weighted average life			5 years
Common stock and warrant unit | Units issued four
Stockholders Equity Note [Line Items]
Number of units issued			8,125,000
Units issue price			0.04
Proceeds from sale of units			$325,000
Number of common stock represents by unit			1
Common stock shares issued			8,125,000
Exercise price	$0.04		$0.04
Weighted average life			5 years
Common stock and warrant unit two
Stockholders Equity Note [Line Items]
Number of units issued		4,660,000
Units issue price		0.25
Number of common stock represents by unit		1
Number of warrants represents by unit		0.75
Common stock shares issued		4,660,000
Number of warrants to purchase common stock		3,495,000
Exercise price		$0.25
Weighted average life		5 years
Common stock and warrant unit three
Stockholders Equity Note [Line Items]
Number of units issued				244,000
Units issue price				0.25
Number of common stock represents by unit				1
Number of warrants represents by unit				0.75
Common stock shares issued				244,000
Number of warrants to purchase common stock				183,000
Exercise price				$0.25
Weighted average life				5 years
Common stock and warrant unit four
Stockholders Equity Note [Line Items]
Number of units issued				2,452,400
Units issue price				0.25
Number of common stock represents by unit				1
Number of warrants represents by unit				0.75
Common stock shares issued				2,452,400
Number of warrants to purchase common stock				1,839,300
Exercise price				$0.25
Weighted average life				5 years

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (USD $)	12 Months Ended	3 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Mar. 30, 2015	Jan. 05, 2015	Jan. 31, 2015	Feb. 12, 2015
Subsequent Event [Line Items]
Number of warrants to purchase common stock	17,272,300
Exercise price	$0.15
Weighted average life	4 years 7 months 13 days
Consultant
Subsequent Event [Line Items]
Shares issued for services rendered (in shares)		3,572,000
Price per share		$0.25
Employee and Consultant
Subsequent Event [Line Items]
Shares issued for services rendered (in shares)			1,073,000
Price per share			$0.25
Subsequent Event
Subsequent Event [Line Items]
Shares issued for services rendered (in shares)				8,683,333
Price per share				$0.03
Subsequent Event | Common stock and warrant unit
Subsequent Event [Line Items]
Number of units issued in satisfaction of accrued liabilities					8,146,225
Units issue price					0.04
Number of common stock represents by unit					1
Common stock shares issued					8,146,225
Number of warrants to purchase common stock					8,146,225
Exercise price					$0.04
Weighted average life					5 years
Subsequent Event | Consultant
Subsequent Event [Line Items]
Shares issued for services rendered (in shares)						3,700,000
Price per share						$0.04
Subsequent Event | Employee and Consultant
Subsequent Event [Line Items]
Shares issued for services rendered (in shares)							15,250,000
Price per share							$0.03
Subsequent Event | Employee and Consultant | Options
Subsequent Event [Line Items]
Number of options issued to purchase shares							10,375,000
Options price per share							$0.03
Fair value of options at date of grant							$201,619
Share based compensation							$201,619
Fair value estimation method							Black-Scholes option pricing model
Grant date exercise price							$0.03
Expected life of option							2 years 6 months 0 days
Expected volatility							211.10%
Expected dividends on stock							0.00%
Risk free interest rate							1.02%